Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area

Main Article Content

Craig Leonardi
Department of Dermatology, St. Louis Medical School, St. Louis, MO

Linda Stein Gold
Henry Ford Hospital, Detroit, MI

Edward Lain
Austin Institute for Clinical Research, Austin, TX

Andrea Neimann
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY

Abby Jacobson
Ortho Dermatologics*, Bridgewater, NJ

Keywords

Psoriasis, Plaque Psoriasis, Topical, Steroid, Retinoid, Halobetasol, Tazarotene

Abstract

Abstract not available.

References

1. Elmets CA, et al. J Am Acad Dermatol. Online ahead of print,
2020 Jul 30. doi:10.1016/j.jaad.2020.07.087.

2. Tanghetti E, et al. J Dermatolog Treat. 2019:1‑8.

3. Kircik LH, et al. J Drugs Dermatol. 2019;18(3):279-284.

4. Strober B, et al. J Am Acad Dermatol. 2020;82(1):117-122.

5. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.

6. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855‑861.

7. Basra MK, et al. Dermatology. 2015;230(1):27-33.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.78

Article Details

How to Cite
[1]
Leonardi, C., Stein Gold, L., Lain, E., Neimann, A. and Jacobson, A. 2020. Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s78. DOI:https://doi.org/10.25251/skin.4.supp.78.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Author Biography

Abby Jacobson, Ortho Dermatologics*, Bridgewater, NJ

*Ortho Dermatologics is a division of Bausch Health US, LLC.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>